ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0425

Upadacitinib Pharmacokinetics and Exposure-Response Relationships for Efficacy and Safety in Axial Spondyloarthritis – Analyses of the Phase 3 Studies (SELECT-AXIS 1 and 2)

Sumit Bhatnagar1, Doerthe Eckert2, Sven Stodtmann2, In-Ho Song3, Peter Wung3, Wei Liu3 and Mohamed-Eslam Mohamed3, 1AbbVie, Highland Park, IL, 2AbbVie, Ludwigshafen, Germany, 3AbbVie, Inc., North Chicago, IL

Meeting: ACR Convergence 2022

Keywords: Ankylosing spondylitis (AS), spondyloarthritis

  • Tweet
  • Email
  • Print
Session Information

Date: Saturday, November 12, 2022

Title: Spondyloarthritis Including PsA – Treatment Poster I: AxSpA

Session Type: Poster Session A

Session Time: 1:00PM-3:00PM

Background/Purpose: The efficacy and safety profile of 15 mg once-daily (QD) upadacitinib (UPA), an oral, reversible, JAK inhibitor has been established in axial spondyloarthritis (axSpA), which includes ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA), through the Phase 2/3 SELECT-AXIS 11 (AXIS 1) study and the Phase 3 studies within SELECT-AXIS 2 (AXIS 2). AXIS 1 studied AS subjects who were naïve to biologic disease modifying anti-rheumatic drug (bDMARD) and AXIS 2 included two independent studies: subjects with AS, who were bDMARD inadequate responders (IR), and subjects with nr-axSpA. The analyses presented here characterize UPA pharmacokinetics and exposure-response relationships for efficacy and safety endpoints using data from all three studies.

Methods: Pharmacokinetic samples were obtained from a pre-specified subset of bDMARD-IR AS (N = 81) and nr-axSpA (N = 71) subjects from AXIS 2 who were included in the analyses, while 92 subjects from AXIS 1 were included in the analyses. UPA pharmacokinetics were characterized in axSpA subjects using a previously established model based on data from healthy subjects and subjects with rheumatoid arthritis (RA)3. Covariates included in the model were indication (RA or axSpA compared to healthy subjects), creatinine clearance, and body weight on apparent oral clearance as well as body weight on apparent central volume of distribution. Efficacy data from the two studies with AS subjects were integrated for those who received placebo and UPA 15mg QD. UPA pharmacokinetics from AXIS 1 were previously analyzed2. Exposure-response analyses for efficacy were conducted using logistic regression modeling to characterize the relationships between UPA average plasma concentration during a dosing interval (Cavg) and the percentage of subjects achieving Assessment of SpondyloArthritis international Society (ASAS)20 and ASAS40 at Week 14. Exposure-response analyses for safety were conducted by graphical assessment for trends with UPA Cavg.

Results: The population pharmacokinetic model adequately described UPA pharmacokinetics in subjects with axSpA. UPA pharmacokinetics and model-predicted plasma exposures in subjects with axSpA were comparable to those in subjects with RA (Table 1).

Exposure-response analyses for efficacy demonstrated no clear exposure-response relationships for ASAS20 or ASAS40 in subjects with AS or nr-axSpA, indicating that exposures associated with UPA 15 mg QD maximized efficacy in subjects with axSpA. There were no clear trends for the relationships between UPA Cavg and the percentage of subjects experiencing lymphopenia (Grade ≥ 3), neutropenia (Grade ≥ 3), > 2 g/dL decrease in hemoglobin from baseline, any infection, serious infections, herpes zoster, or pneumonia through Week 14.

Conclusion: Pharmacokinetic analyses showed that UPA pharmacokinetics are similar between subjects with RA and axSpA. The exposure-response analyses demonstrated that plasma exposures associated with UPA 15 mg QD maximize efficacy in subjects with axSpA, supporting the use of UPA 15 mg QD as the optimal dose across the different axSpA disease subpopulations.

Supporting image 1

Supporting image 2


Disclosures: S. Bhatnagar, AbbVie; D. Eckert, AbbVie; S. Stodtmann, AbbVie; I. Song, AbbVie; P. Wung, AbbVie; W. Liu, AbbVie; M. Mohamed, Abbvie.

To cite this abstract in AMA style:

Bhatnagar S, Eckert D, Stodtmann S, Song I, Wung P, Liu W, Mohamed M. Upadacitinib Pharmacokinetics and Exposure-Response Relationships for Efficacy and Safety in Axial Spondyloarthritis – Analyses of the Phase 3 Studies (SELECT-AXIS 1 and 2) [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/upadacitinib-pharmacokinetics-and-exposure-response-relationships-for-efficacy-and-safety-in-axial-spondyloarthritis-analyses-of-the-phase-3-studies-select-axis-1-and-2/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/upadacitinib-pharmacokinetics-and-exposure-response-relationships-for-efficacy-and-safety-in-axial-spondyloarthritis-analyses-of-the-phase-3-studies-select-axis-1-and-2/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology